Treatment of B-cell lymphomas using a CD40 binding protein that inhibits the binding of CD40 to CD40L

摘要

The specification describes a method for treating b-cell lymphomas characterized by neoplastic cells that express CD40. The method involves administering a therapeutically effective amount of a CD40 binding protein in a pharmaceutically acceptable buffer. CD40 binding proteins include monoclonal antibodies to CD40, and CD40 ligand. CD40 binding proteins may also be used to prevent disease characterized by neoplastic cells that express CD40.